DK0604418T3 - Isolerede viralproteincytokinantagonister - Google Patents

Isolerede viralproteincytokinantagonister

Info

Publication number
DK0604418T3
DK0604418T3 DK91917100T DK91917100T DK0604418T3 DK 0604418 T3 DK0604418 T3 DK 0604418T3 DK 91917100 T DK91917100 T DK 91917100T DK 91917100 T DK91917100 T DK 91917100T DK 0604418 T3 DK0604418 T3 DK 0604418T3
Authority
DK
Denmark
Prior art keywords
cytokine antagonists
isolated viral
viral protein
protein cytokine
disclosed
Prior art date
Application number
DK91917100T
Other languages
English (en)
Inventor
Craig A Smith
Raymond G Goodwin
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK0604418T3 publication Critical patent/DK0604418T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DK91917100T 1991-03-29 1991-03-29 Isolerede viralproteincytokinantagonister DK0604418T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1991/002207 WO1992017583A1 (en) 1991-03-29 1991-03-29 Isolated viral protein cytokine antagonists

Publications (1)

Publication Number Publication Date
DK0604418T3 true DK0604418T3 (da) 1999-06-14

Family

ID=22225427

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91917100T DK0604418T3 (da) 1991-03-29 1991-03-29 Isolerede viralproteincytokinantagonister

Country Status (8)

Country Link
EP (1) EP0604418B1 (da)
JP (1) JPH06508502A (da)
AT (1) ATE171471T1 (da)
AU (1) AU646695B2 (da)
DE (1) DE69130262T2 (da)
DK (1) DK0604418T3 (da)
ES (1) ES2123515T3 (da)
WO (1) WO1992017583A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495515B1 (en) 1995-04-19 2002-12-17 Viron Therapeutics, Inc. Chemokine binding protein and methods of use therefor
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0901379T3 (da) * 1996-05-22 2000-12-27 Univ Alberta Type 2-kemokinbindende proteiner og metoder til anvendelse deraf
EP1034789A1 (en) * 1996-05-22 2000-09-13 University Of Alberta Type-2 chemokine binding proteins and methods of use therefor
WO2000021981A2 (de) * 1998-10-09 2000-04-20 Bioserv Ag TNFα BINDENDE PEPTIDE UND IHRE ANWENDUNG FÜR DIE DETEKTION, INAKTIVIERUNG UND/ODER ENTFERNUNG VON TNFα AUS BIOLOGISCHEN FLÜSSIGKEITEN
US6589933B1 (en) 1999-04-02 2003-07-08 Viron Therapeutics, Inc. Myxoma chemokine binding protein
WO2001040489A1 (en) * 1999-11-30 2001-06-07 Novo Nordisk Biotech, Inc. Methods for producing a polypeptide using a consensus translational initiator sequence
US6894155B2 (en) 2000-10-11 2005-05-17 Viron Therapeutics Nucleic acid molecules and polypeptides for immune modulation
DE60128950T2 (de) 2000-12-04 2008-02-28 Viron Therapeutics, Inc., London Immunmodulatorisches Protein abgeleitet vom Yaba-Affentumor-Virus
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CN101500607B (zh) 2005-05-16 2013-11-27 阿布维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
AU630497B2 (en) * 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors

Also Published As

Publication number Publication date
AU646695B2 (en) 1994-03-03
ATE171471T1 (de) 1998-10-15
EP0604418A1 (en) 1994-07-06
AU8656991A (en) 1992-11-02
WO1992017583A1 (en) 1992-10-15
ES2123515T3 (es) 1999-01-16
JPH06508502A (ja) 1994-09-29
DE69130262T2 (de) 1999-03-18
EP0604418B1 (en) 1998-09-23
DE69130262D1 (de) 1998-10-29

Similar Documents

Publication Publication Date Title
DK0604418T3 (da) Isolerede viralproteincytokinantagonister
DK0409472T3 (da) Knoglemorfogenetisk protein
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
BR0013231A (pt) Complexos citocina-anticorpo múltiplos
CY1113421T1 (el) Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα
DK0392300T3 (da) Anvendelse af lægemidler, der indeholder mindst et cytokin, til systemisk behandling af præneoplastiske læsioner
NO831317L (no) Fremgangsmaate for fremstilling av funksjonelle menneske-urokinase proteiner.
NO923953D0 (no) Peptider
DE59101397D1 (de) O-glycosyliertes ifn-alpha.
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
MX7599E (es) Procedimiento biotecnologico para la sintesis de la proteina g del virus de la estomatitis vesicular
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
SE9602822D0 (sv) New receptor
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
IT8423517A0 (it) Composizione farmaceutica per combattere infezioni virali, eprocedimento di uso per le infezioni virali.
DK190983D0 (da) 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmade til deres fremstilling og mellemprodukter derfor
CA2080355A1 (en) Isolated Viral Protein Cytokine Antagonists
SE9604439D0 (sv) New receptor
WO1991013984A3 (en) Interleukin-4 binding proteins
ATE102252T1 (de) Rekombinantes gefluegelpockenvirus, expressionsvektoren fuer heterologische proteine und davon derivierte gefluegelvakzine.
DK2990D0 (da) Valleproteinpraeparat, fremgangsmaade til fremstilling og anvendelse deraf
IT8921396A0 (it) Procedimento per la sintesi di peptidi preventivamente identificati come siti di interazione di proteine interagenti.